Serac Life Sciences Limited (SLS) has been established to build a portfolio of medical imaging technologies which can help deliver personalised medicine – ensuring patients receive the right treatment at the right time, resulting in improved outcomes, better quality of life and more efficient use of healthcare resources.
We’re using our deep industry knowledge to identify and acquire dormant assets – i.e. technologies which have been taken to a relatively late stage of development but no longer fit within a company’s strategy so lack direction and/or focus.
Supported by Serac, Serac Life Sciences is able to bring together profound expertise in delivering insight and people driven approaches to strategy and innovation, in combination with a management team with over 80 years’ experience in the global development and successful commercialisation of medical imaging technologies.
With the acquisition of maraciclatide from GE we have taken the first step towards building a portfolio of assets which we believe can create value by making a substantial difference to patients and healthcare systems around the world.
For investors: firstname.lastname@example.org
For other enquiries: email@example.com
Serac Healthcare is a wholly owned subsidiary of SLS developing maraciclatide, a molecular imaging tracer acquired from GE Healthcare to help rheumatologists deliver personalised medicine to their patients with rheumatoid arthritis (RA).
Breakthroughs in Molecular Imaging Technologies
Serac Imaging Systems, a wholly owned subsidiary of SLS, is developing a highly innovative, miniature, hybrid gamma/optical camera (HGC) which will be portable, cheaper, smaller and easier to use than anything that exists on the market today. Taking the benefits of molecular imaging to the patient – whether in the Nuclear Medicine Department, in the operating room, in the intensive care unit, in the physician’s office or even in a remote village in a developing country.